News

Prescription medicines cause an estimated 100,000 deaths each year in the US—the fourth leading cause of preventable death. One might ask, since the pharmaceutical industry is required to spend billions of research dollars to generate scientific information on new drugs, how could such harm still occur?

An innovative and novel concept was described in a recent Commentary in Clinical Pharmacology & Therapeutics, calling for the development and implementation of a potentially transformative medical-decision support technology described as “medication autopilots” by the authors.

Changes made for gatifloxacin, quetiapine and Ziprasidone

Update to QTdrugs Lists

The safe use of the CredibleMeds® lists of QT-prolonging medications requires being aware of any changes that are mede to the lists. Therefore, we wish to inform you of the following changes.

Changes made to classification of some antidepressants

Donepezil and cilostazol added to the list of of drugs with Known Risk of TdP. Torsemide added to the list of drugs with Conditional Risk of TdP. Atomoxetine added to the list of drugs with Possible Risk of TdP.

Fosphenytoin removed from two lists, Ciprofloxacin and Fluconazole moved to Known Risk of TdP list, and Propofol added to the list of drugs with Known Risk of TdP.

Everyone in DC knows that the FDA Commissioner’s job is the most difficult appointed position in government.

This one-day CME course organized by Dr. Glenn Fishman and Dr. Silvia Priori will focus on inherited arrhythmogenic diseases that can cause sudden arrhythmic death. A panel of internationally recognized experts will cover updates on long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and arrhythmogenic cardiomyopathy (ARVC).